Search Results
Apr 13, 2026, 20:00 ET Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
that after treatment with sac-TMT in combination with pembrolizumab, the objective response rate (ORR) in the total population was 51% and 54% in IO-pretreated population. The median PFS was 7.3 months and the median OS reached 18.9 months in the total population. Furthermore, the safety profile
More news about: Kelun-Biotech
Apr 13, 2026, 10:00 ET Bringing Agentic Finance to Telegram: Byreal Debuts RealClaw, Transitioning Onchain Finance to an Agent-First Economy
https://github.com/byreal-git/byreal-agent-skillsInstallation: npm install -g @byreal-io/byreal-cliDocumentation:
More news about: Byreal
Apr 13, 2026, 09:54 ET Bringing Agentic Finance to Telegram: Byreal Debuts RealClaw, Transitioning Onchain Finance to an Agent-First Economy
https://github.com/byreal-git/byreal-agent-skillsInstallation: npm install -g @byreal-io/byreal-cliDocumentation:
More news about: Byreal
Apr 09, 2026, 07:35 ET La rinascita di una leggenda: l'America torna a contendersi la 38ª edizione della America's Cup Louis Vuitton
scrivere il primo capitolo di una nuova era nella storia dell'America's Cup. Visto lo straordinario slancio che si sta creando attorno alla Coppa, Karel ed io siamo orgogliosi di contribuire a riportare la nazione di maggiore successo al mondo su questo palcoscenico iconico, al fianco di alcuni dei marchi americani
More news about: American Racing Challenger Team USA
Apr 08, 2026, 08:30 ET Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients
groundbreaking AI-driven molecular insight for a subset of mono-immunotherapy eligible non-small cell lung cancer (NSCLC) patients. The NSCLC immunotherapy (IO) treatment selection signature was developed to determine which patients benefit from the addition of chemotherapy versus those who are harmed by the
More news about: Caris Life Sciences
Apr 07, 2026, 02:05 ET Eluvio Introduces Inline Frame-Accurate Video Intelligence and Next-Gen Eluvio Video Intelligence Editor (EVIE) with New Advanced AI Tools for Agentic Orchestration of Title Libraries and Live Sports at NAB 2026
patents and has won the Seicon Grand Prize and Hollywood Professional Association Engineering Excellence Award. @EluvioInc | linkedin.com/company/eluv-io
More news about: Eluvio, Inc.
Apr 07, 2026, 02:00 ET Eluvio Announces Unified Platform for Zero-Copy Broadcast Distribution, D2C OTT Streaming & Monetization, and Inline AI Video Intelligence with Commercial Availability of Content Fabric "Bucharest Release"
https://www.linkedin.com/company/eluv-io/
More news about: Eluvio, Inc.
Apr 02, 2026, 12:01 ET d-Matrix Boosts Rack-scale AI Capabilities With Acquisition of GigaIO Data Center Business
pioneering accelerated computing for AI inference, breaking through the limits of latency, cost and energy. Its Corsair compute accelerators, JetStream IO accelerators, and Aviator software deliver fast, sustainable AI inference at data center scale. Learn more at
More news about: d-Matrix
Apr 02, 2026, 10:14 ET Ultra Pure Celebrates 20 Years of Leadership, Innovation, and Reliability in the Bulk Alcohol Industry
https://www.youtube.com/watch?v=Io1IAvHVQ_MCheck out the NPR planet Money Episode 826 "The Vodka Proof"
More news about: Ultra Pure, LLC
Apr 02, 2026, 08:01 ET United Rugby Championship Achieves Transformative First-Year Results with Eluvio: Slashes Streaming Costs, Dramatically Increases Revenue and Expands Global Audience
and holds 15 issued US patents. On X: @EluvioInc | LinkedIn: https://www.linkedin.com/company/eluv-io/
More news about: Eluvio, Inc.
Apr 01, 2026, 12:37 ET NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
Toward Precision Oncology in Osteosarcoma" and "Characterizing the Peripheral T-cell Repertoire in Patients with Unresectable Melanoma Treated with IO102-IO103 and Nivolumab-relatlimab."The posters included an abstract from Taneal D. Carter, DHSc, MPA, MS, Senior Manager of the NCCN Cancer Care
More news about: National Comprehensive Cancer Network
Apr 01, 2026, 11:30 ET Reengineering Start of Care: IO Health Launches ioDoc, Eliminating Manual Documentation at the Point of Care
reduced per episodePASADENA, Calif., April 1, 2026 /PRNewswire/ -- IO Health, a health technology company serving U.S. home health and hospice agencies, today announced the commercial availability of ioDoc™, a digital patient
More news about: io Health
Apr 01, 2026, 08:06 ET NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
Toward Precision Oncology in Osteosarcoma" and "Characterizing the Peripheral T-cell Repertoire in Patients with Unresectable Melanoma Treated with IO102-IO103 and Nivolumab-relatlimab."The posters included an abstract from Taneal D. Carter, DHSc, MPA, MS, Senior Manager of the NCCN Cancer Care
More news about: National Comprehensive Cancer Network
Mar 27, 2026, 09:15 ET Scalable Biotech Manufacturing Unlocks a $14B Market
ImmunityBio is positioned to translate its cell banking infrastructure into first-in-human clinical programs at scale. NCI-presented preclinical data from AACR IO 2026 also showed M-ceNK cells combined with ANKTIVA® produced statistically significant tumor volume reductions in two SCLC xenograft models.Fate
More news about: USA News Group
Mar 27, 2026, 07:07 ET Natural Grocers® and Rodale Institute Celebrate Earth Month With Annual Ladybug Love Campaign, April 1-30, 2026
Open only to legal residents of states in which Natural Grocers currently has store locations, 18 years or older at the time of entry: AZ, AR, CO, ID, IO, KS, LA, MN, MO, MT, NB, NV, NM, ND, OK, OR, SD, TX, UT, WA and WY. Void where prohibited by law. For Official Rules and complete details, visit
More news about: Natural Grocers by Vitamin Cottage, Inc.
Mar 26, 2026, 23:54 ET Akeso Reports Full-Year 2025 Financial Results
clinical benefits across multiple tumor types. Its exceptional efficacy in treating challenging cases, such as IO-resistant and "cold" tumors, has solidified its status as a cornerstone therapy in the IO 2.0 era.Akeso is advancing 12 registrational or Phase III clinical trials for cadonilimab globally,
More news about: Akeso, Inc.
Mar 26, 2026, 09:32 ET CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
ORR reached 90% with a DCR of 100%, while the ORR was 25% in IO-pretreated NSCLC (AGA-negative). Furthermore, significant benefits were observed in patients with heavily pre-treated "cold tumors," achieving an
More news about: CStone Pharmaceuticals
Mar 26, 2026, 08:53 ET CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
achieved an ORR of 90% in patients with PD-L1 TPS ≥ 50%. Significant benefits were also observed in historically difficult-to-treat 'cold tumors', including IO-pretreated advanced NSCLC, non-clear cell renal cell carcinoma (nccRCC), and soft tissue sarcoma (STS). Furthermore, Phase II studies evaluating CS2009
More news about: CStone Pharmaceuticals
Mar 26, 2026, 06:00 ET Innovent Announces 2025 Annual Results and Business Updates
(PD-1/IL-2α-bias): Next-gen IO cornerstone, potential TAM over US$40 billion for first wave of indicationsIn collaboration with Takeda, IBI363 is being advanced globally. The first global MRCT Phase 3 in IO-resistant squamous NSCLC has been initiated. PoC in IO-resistant non-squamous
More news about: Innovent Biologics
Mar 24, 2026, 22:40 ET Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
continues to extend its global IO 2.0 leadership into broader, high-impact combination strategies. Beyond the "IO 2.0 + ADC 2.0" portfolio, the Company is advancing a comprehensive portfolio of novel combination approaches aimed at addressing major unmet clinical needs. These include IO 2.0 combinations with
More news about: Akeso, Inc.
Mar 24, 2026, 05:02 ET Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC
our novel DC strategy, further solidifying our core technical advantages in the ADC field," said Dr. Michael Ge, CEO of Kelun-Biotech. "Innovation in IO and ADC is currently reshaping the global cancer treatment landscape. Leveraging our systematic and platform-based R&D capabilities and extensive
More news about: Kelun-Biotech
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
demonstrating the industry's high recognition of the Company's independent R&D technology platforms.Exploration of IO2.0+ADC Combination TherapiesNext-generation IO+ADC combination therapy is a core development trend in the global biopharmaceutical industry. The "bispecific antibody +
More news about: Duality Biotherapeutics, Inc.
Mar 21, 2026, 13:43 ET Arcfra AECP 6.3 Menembus Batasan Performa 11 Juta IOPS, Hadirkan Performa "All-Flash" Kelas Premium dan Ketahanan RPO=0 untuk "Cloud Enterprise"
100 μs pada Random Read 4K.Pencapaian ini didukung oleh integrasi Intel® Data Streaming Accelerator (DSA), rangkaian IO_uring yang lebih modern, serta penggunaan volume virtual 8-stripe yang memaksimalkan paralelisme penyimpanan tanpa perlu konfigurasi manual.Kesinambungan
More news about: Arcfra
Mar 20, 2026, 10:35 ET Arcfra AECP 6.3 phá vỡ rào cản IOPS 11M, mang lại hiệu năng All-Flash cấp Tier 1 và khả năng phục hồi RPO=0 cho dịch vụ đám mây doanh nghiệp
đọc ngẫu nhiên 4K.Những đột phá này được thúc đẩy bởi tích hợp Intel® Data Streaming Accelerator (DSA), một ngăn xếp IO_uring hiện đại hóa, và ổ đĩa ảo 8-stripe, giúp tối đa hóa tính song song của lưu trữ mà không cần tinh chỉnh thủ công.Duy trì hoạt động
More news about: Arcfra
Mar 20, 2026, 10:29 ET 아크프라 AECP 6.3, 1100만 IOPS 장벽 돌파… 엔터프라이즈 클라우드를 위한 티어-1 올플래시 성능과 RPO=0 복원력 제공
GiB/s(3.6배 향상)4K 랜덤 읽기에서 100μs 미만 지연 시간이러한 혁신은 인텔®(Intel®) 데이터 스트리밍 가속기(Data Streaming Accelerator, DSA) 통합, 현대화된 IO_uring 스택, 수동 튜닝 없이 스토리지 병렬성을 극대화하는 8-스트라이프 가상 볼륨에 의해 이루어졌다.미션 크리티컬을 위한 무위험 비즈니스 연속성미션 크리티컬 워크로드를 보호하기 위해, AECP 6.3은 실시간
More news about: Arcfra